Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 1, 2006, Pages 22-33

  Ren, Xiubao ^a   Yu, Jinpu ^a   Liu, Hong ^a   Zhang, Peng ^a   An, Xiumei ^a   Zhang, Naining ^a   Hao, Xishan ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Antitumor immunity; CIK; Solid tumor; Th1 bias

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS CYTOKINE INDUCED KILLER CELL; CANCER MORTALITY; CANCER RELAPSE; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOLYSIS; DISEASE SEVERITY; DRUG CYTOTOXICITY; FEASIBILITY STUDY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; KILLER CELL; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; TH1 CELL; TUMOR CELL LINE; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; CELL LINE, TUMOR; CYTOKINES; FEMALE; HUMANS; KILLER CELLS; MIDDLE AGED; NEOPLASMS; TH1 CELLS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33644896510     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.22     Document Type: Article

References (15)

1. + killer cells. Ann Hematol 1997;74:51.
2. Margolin KA, Negrin RS, Wong KK, et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997;157:231.
3. + cells derived from T-cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687.
4. Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996;169:85.
5. Hoyle C, Bangs CD, Chang P, et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998;92:3318.
6. Verneris MR, Kornacker M, Mailander V, et al. Resistance of ex vivo expanded CD3+CD56+ T-cells to Fas-mediated apoptosis. Cancer Immunol Immunother 2000;49:335.
7. Scheffold C, Brandt K, Johnston V, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transp 1995;15:33.
8. Muller M, Scheffold C, Lefterova P, et al. Potential of autologous immunologic effector cells for prediction of progression of disease in patients with chronic myelogenous leukemia. Leuk Lymphoma 1998;31:335.
9. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002;116:78.
10. Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer, and lymphoma. Br J Cancer 1999;81:1009.
11. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon: Lysis of natural killer resistant fresh solid lymphocytes. J Exp Med 1982;155:1823.
12. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986;233:1318.
13. + killer cells. Blood 1995;86:3493.
14. Mori T, Takada R, Watanabe R, et al. T-helper(Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother 2001;50:566.
15. Sato M, Goto S, Kaneko R, et al. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 1998;18:3951.